Search
Tynecon's subsidiary, Bochuangyuan, has announced promising results from the Phase II clinical trial of its groundbreaking Class 1 innovative drug, CKBA Ointment, for the treatment of vitiligo. The trial demonstrated significant efficacy and favorable safety profiles, fully meeting expectations and paving the way for subsequent Phase III trials. CKBA Ointment stands as the first-in-class (FIC) innovative small molecule drug specifically targeting the T-cell fatty acid metabolism pathway, offering vast potential in the realm of autoimmune diseases.
The company intends to expedite the Phase III clinical trial for vitiligo and advance the Phase II/III clinical trial for rosacea. Additionally, Bochuangyuan will further delve into the mechanism of action of CKBA Ointment and explore its potential in treating additional medical conditions.
-
C114 Communication Network -
Communication Home
